On September 28, 2017, The U.S. Food and Drug Administration approved Verzenio (abemaciclib) to treat adult patients who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer that has progressed after taking therapy that alters a patient’s hormones (endocrine therapy). Many thanks to the Breast Group for their hard work on BRS0044, a Phase 3 Eli Lilly trial that studied this drug. More information can be found on the FDA’s press release.